This brand name is authorized in United States. It is also authorized in Japan.
The drug BREZTRI contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
Q3OKS62Q6X - BUDESONIDE
|
|
Budesonide is a glucocorticosteroid with a high local anti-inflammatory effect. At doses clinically equivalent to systemically acting glucocorticosteroids, budesonide gives significantly less HPA axis suppression and has a lower impact on inflammatory markers. |
|
2
|
UNII
V92SO9WP2I - GLYCOPYRROLATE
|
|
Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways. |
|
3
|
UNII
5ZZ84GCW8B - FORMOTEROL
|
|
Formoterol is a predominantly selective β2-stimulator. Formoterol has bronchodilator activity in patients with reversible obstructive airway diseases. In humans formoterol is effective in the prophylaxis of bronchospasm induced by methacholine challenge. |
|
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| JP | 医薬品医療機器総合機構 | 2290805G1027, 2290805G2023 |
| US | FDA, National Drug Code | 0310-4616 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.